MIT Technology Review @techreview
The FDA just narrowly backed Merck’s covid pill, but updated data last week from 1,433 patients found the drug, called molnupiravir, cut the risk of hospitalization or death by only 30%. That figure is down from initial results of 50% in October. https://t.co/iKDMHvpQHL — PolitiTweet.org